Introduction 

Tumoral calcinosis (TC) is a rare condition characterised by the formation of calcific deposits in the periarticular tissues of the body. Although the exact aetiology of TC is not fully understood, the disorder is frequently associated with hyperphosphatemia and abnormalities in mineral metabolism.¹ Parathyroid hormone (PTH) plays a critical role in calcium and phosphate homeostasis, and its involvement in the pathogenesis of TC has garnered significant scientific interest.

The role of PTH in TC is multifaceted and complex. It involves the regulation of serum calcium and phosphate levels, which may contribute to the precipitation of calcium phosphate crystals in soft tissues.² This article will explore the pathophysiological mechanisms of PTH in the development of TC, the clinical implications of these findings, and potential therapeutic strategies targeting the parathyroid hormone regulatory axis.

Understanding the interaction between PTH and phosphate metabolism is crucial for developing effective treatments for TC. This article aims to provide a comprehensive overview of the current knowledge on the subject, highlighting the latest research and potential directions for future investigation.

Pathophysiology of tumoral calcinosis and the role of PTH 

Tumoral calcinosis is traditionally characterised by large, lobulated calcifications primarily located around major joints such as the hips, shoulders, and elbows. It is most commonly seen in patients with renal failure, where phosphate clearance is compromised.³ The relationship between PTH and phosphate is critical in understanding TC development, especially in hyperparathyroid states where PTH secretion is dysregulated.

Parathyroid hormone maintains calcium and phosphate homeostasis through its actions on the kidneys, bones, and intestines. PTH stimulates phosphate excretion and calcium reabsorption in the kidneys, which can paradoxically lead to hyperphosphatemia when renal function is impaired.⁴ In bones, PTH facilitates the release of calcium and phosphate into the bloodstream, contributing to an imbalance that favours calcification in soft tissues.

Recent studies have suggested that alterations in PTH receptors or signalling pathways may predispose individuals to aberrant calcification processes seen in TC.⁵ Additionally, the role of other hormonal pathways, including fibroblast growth factor 23 (FGF23), which is known to be involved in phosphate metabolism, has been explored to elucidate their interplay with PTH in the pathogenesis of TC.

Clinical manifestations and diagnosis 

The clinical presentation of tumoral calcinosis can vary significantly, but typically, patients present with painless, firm masses near joints. These masses may become painful or infected, leading to significant morbidity.⁶ Diagnosis is primarily based on the radiological appearance of calcified masses in periarticular tissues, which are well-defined on X-rays and CT scans.

Biochemical tests often reveal hyperphosphatemia, normal or elevated levels of calcium, and normal or slightly elevated levels of PTH. It is crucial to differentiate tumoral calcinosis from other conditions, such as calciphylaxis and metastatic calcification, particularly in patients with renal disease.⁷ Advanced imaging techniques and histopathological examination following biopsy can help confirm the diagnosis by demonstrating calcium deposits surrounded by a fibrous capsule.

Given the role of PTH in calcium and phosphate dysregulation, it is essential to assess parathyroid function and rule out primary hyperparathyroidism or other glandular dysfunctions as part of the diagnostic workup.

Therapeutic approaches and management 

The management of tumoral calcinosis focuses on controlling pain, preventing infection, and reducing phosphate levels in the blood. Dietary phosphate restriction and phosphate binders are typically first-line treatments to manage hyperphosphatemia.⁸ In cases where PTH levels are elevated, medications such as calcimimetics can be used to reduce PTH secretion and subsequent phosphate release from bones.⁹

Surgical removal of calcific deposits may be indicated for relief of symptoms or if there is concern for infection or ulceration. Surgery, however, does not address the underlying metabolic disorder and is often followed by the recurrence of calcifications.¹⁰

Emerging therapies targeting the FGF23 and PTH regulatory axis are currently under investigation. These include the use of monoclonal antibodies that modify the activity of these hormones, potentially reducing abnormal calcifications in patients with TC.¹¹ Ongoing research into the molecular mechanisms of TC promises to open new avenues for targeted therapies that address the root causes of the disorder.

Genetic and molecular mechanisms linking PTH to tumoral calcinosis 

Recent advancements in molecular biology and genetics have shed light on the intricate relationship between parathyroid hormone (PTH) and the development of tumoral calcinosis (TC). PTH, a principal regulator of calcium and phosphate metabolism, exerts its effects through the PTH/PTH-related peptide receptor, which activates multiple signalling pathways involved in bone remodelling and mineral ion homeostasis. Disruptions in these pathways, due to genetic mutations or alterations in gene expression, can lead to aberrant calcium-phosphate product deposition, a hallmark of TC.¹²

One significant area of interest is the role of the GALNT3 gene, which encodes a glycosyltransferase responsible for the O-linked glycosylation of the FGF23 protein. Mutations in GALNT3 have been linked to familial tumoral calcinosis, where they cause hyperphosphatemia by reducing the activity of FGF23, a hormone that normally acts to decrease serum phosphate levels by reducing renal phosphate reabsorption.¹³ The resultant hyperphosphatemia is a critical factor in the precipitation of calcium phosphate in periarticular tissues, leading to TC.

Moreover, the regulatory relationship between PTH and FGF23 is crucial; PTH stimulates the secretion of FGF23 from osteocytes and osteoblasts, which in turn acts to suppress PTH synthesis in a feedback loop. Mutations or dysregulation in this axis can disrupt the delicate balance required to maintain normal levels of serum phosphate and calcium. For instance, excessive PTH secretion in hyperparathyroid states can override the phosphate-lowering effects of FGF23, contributing to the phosphate elevations seen in TC patients.¹⁴

Another layer of complexity is added by the Klotho gene, which encodes a co-receptor for FGF23. Variants in Klotho can affect the sensitivity of tissues to FGF23, altering the phosphate and calcium balance and potentially contributing to both sporadic and familial forms of TC. The interaction between PTH, FGF23, and Klotho underscores a highly coordinated network controlling mineral metabolism, which, when disrupted, leads to the pathologies observed in TC.¹¹

Investigations into the genetic underpinnings of TC have also highlighted the role of other genes, such as SLC34A3, which encodes a renal phosphate transporter. Mutations in this gene can lead to hereditary hypophosphatemic rickets with hypercalciuria, a condition that shares some pathophysiological features with TC, such as hyperphosphatemia and calcifications. Understanding these genetic interactions helps clarify the multifactorial nature of TC and suggests that multiple genetic and environmental factors contribute to its aetiology.¹⁵

These genetic and molecular insights not only enhance our understanding of the pathogenesis of tumoral calcinosis but also open new avenues for targeted therapies. For instance, modulating the activity of GALNT3 or enhancing the expression of FGF23 through gene therapy could potentially correct the biochemical abnormalities associated with TC. Similarly, pharmacological agents that mimic or enhance the action of Klotho or modulate PTH receptor sensitivity could offer new therapeutic strategies for managing TC.

Summary

The role of parathyroid hormone in the development of tumoral calcinosis is a complex interplay of genetic, metabolic, and environmental factors. Effective management requires a comprehensive approach that addresses both the symptoms and underlying metabolic disturbances. Advances in understanding the molecular pathways influenced by PTH and related hormones hold promise for the development of targeted therapies that could more effectively treat or even prevent tumoral calcinosis. Continued research and clinical trials are essential to refine these strategies and improve outcomes for patients suffering from this challenging condition.